<SEC-DOCUMENT>0001564590-20-043577.txt : 20200915
<SEC-HEADER>0001564590-20-043577.hdr.sgml : 20200915
<ACCEPTANCE-DATETIME>20200915151446
ACCESSION NUMBER:		0001564590-20-043577
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20200915
DATE AS OF CHANGE:		20200915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Novus Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-237379
		FILM NUMBER:		201175875

	BUSINESS ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>nvus-424b3.htm
<DESCRIPTION>424B3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nvus-424b3.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Filed Pursuant to Rule 424(b)(3)<br />Registration Nos. 333-237379</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">Novus Therapeutics, Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS SUPPLEMENT NO. 1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">TO PROSPECTUS DATED April 3, 2020</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Prospectus Supplement No. 1 supplements and amends the prospectus dated April 3, 2020 (File No. 333-237379) filed by Novus Therapeutics, Inc. (the &#8220;<font style="font-style:italic;">Company</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 14, 2020, the Company announced the acquisition of Anelixis Therapeutics, Inc. by way of merger (the &#8220;<font style="font-style:italic;">Merger</font>&#8221;) and a concurrent offering of Series X<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup> Preferred Stock (&#8220;<font style="font-style:italic;">Preferred Stock</font>&#8221;) for aggregate gross proceeds of approximately $108.1 million (the &#8220;<font style="font-style:italic;">Financing</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Merger, the Company issued approximately 3.8 million shares of Common Stock and issued approximately 146,765 shares of Preferred Stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Financing, the Company issued approximately 217,198 shares of Preferred Stock, which represented a pre-money valuation of the Company at approximately $85 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional information regarding the Merger and Financing will be filed in a Current Report on Form 8-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> You should read this prospectus supplement, together with additional information described under the headings &#8220;Incorporation of Certain Information by Reference&#8221; and &#8220;Where You Can Find More Information&#8221; in the prospectus dated April 3, 2020 carefully before you invest in our securities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus supplement is September 15, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
